Literature DB >> 8125567

Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction.

S Madhavan1, W L Ooi, H Cohen, M H Alderman.   

Abstract

The prognostic value of pretreatment pulse pressure as a predictor of myocardial infarction and the relation of pulse pressure and in-treatment diastolic blood pressure reduction to myocardial infarction were investigated in a union-sponsored systematic hypertension control program. In a prospective study, 2207 hypertensive patients with a pretreatment systolic blood pressure greater than or equal to 160 mm Hg and/or diastolic pressure greater than or equal to 95 mm Hg grouped according to tertile of pulse pressure (PP1, < or = 46; PP2, 47 to 62; PP3, > or = 63 mm Hg) were further stratified by the degree of diastolic fall: large (L), > or = 18; moderate (M), 7 to 17; small (S), < or = 6 mm Hg. During an average follow-up of 5 years, 132 cardiovascular events (50 myocardial infarctions, 23 strokes) were observed. Myocardial infarction rates per 1000 person-years were positively related to pulse pressure (PP1, 3.5; PP2, 2.9; PP3, 7.5; PP3 versus PP1, P = .02). Wide pulse pressure was identified as a predictor of myocardial infarction (PP3 versus [PP1 + PP2]: relative risk [RR] = 2.2, 95% confidence interval [CI] = 1.2-4.1), controlling for other known risk factors by Cox regression. A curvilinear relation (resembling a J shape) between diastolic fall and myocardial infarction was observed in patients with the widest pulse pressure, PP3 (L, 9.5; M, 3.9; S, 11.2; L versus M: RR = 2.5, 95% CI = 1.0-6.2; S versus M: RR = 2.9, 95% CI = 1.1-8.0).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8125567     DOI: 10.1161/01.hyp.23.3.395

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  80 in total

Review 1.  Vascular and valvar calcification: recent advances.

Authors:  A Farzaneh-Far; D Proudfoot; C Shanahan; P L Weissberg
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 2.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 3.  Diastolic pressure, systolic pressure, or pulse pressure?

Authors:  C Vlachopoulos; M O'Rourke
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

4.  Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease.

Authors:  M F O'Rourke
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

5.  Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.

Authors:  Mira Harrison-Woolrych; Simran Maggo; Ming Tan; Ruth Savage; Janelle Ashton
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

6.  Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.

Authors:  Roberto Antonicelli; Stefano Omboni; Di Ciò Giovanni; Roberto Ansuini; Alfredo Mori; Rosaria Gesuita; Gianfranco Parati; Enrico Paciaroni
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Systolic blood pressure.

Authors:  Jan N Basile
Journal:  BMJ       Date:  2002-10-26

Review 8.  Pulse pressure: an important tool in cardiovascular pharmacology and therapeutics.

Authors:  Roland Asmar; Michel Safar; Patrice Queneau
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Arterial aging--hemodynamic changes and therapeutic options.

Authors:  Michel E Safar
Journal:  Nat Rev Cardiol       Date:  2010-08       Impact factor: 32.419

Review 10.  Percutaneous coronary intervention in the elderly.

Authors:  Tracy Y Wang; Antonio Gutierrez; Eric D Peterson
Journal:  Nat Rev Cardiol       Date:  2010-12-07       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.